Article Text

Download PDFPDF
Stepwise radical endoscopic resection for eradication of Barrett's oesophagus with early neoplasia in a cohort of 169 patients
  1. Roos E Pouw1,
  2. Stefan Seewald2,
  3. Joep J Gondrie1,
  4. Pierre H Deprez3,
  5. Hubert Piessevaux3,
  6. Heiko Pohl4,5,
  7. Thomas Rösch4,
  8. Nib Soehendra2,
  9. Jacques J Bergman1
  1. 1Department of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
  2. 2Department of Interdisciplinary Endoscopy, University Hospital Eppendorf, Hamburg, Germany
  3. 3Department of Gastroenterology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
  4. 4Department of Gastroenterology, Charité – Campus Virchow, Berlin, Germany
  5. 5VA White River Junction, Vermont, and Dartmouth–Hitchcock Medical Center, One Medical Center Drive, Lebanon, New Hampshire, USA
  1. Correspondence to Dr Jacques J. Bergman, Department of Gastroenterology and Hepatology, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands; j.j.bergman{at}amc.uva.nl

Abstract

Background and Aims Endoscopic resection is safe and effective to remove early neoplasia (ie,high-grade intra-epithelial neoplasia/early cancer) in Barrett's oesophagus. To prevent metachronous lesions during follow-up, the remaining Barrett's oesophagus can be removed by stepwise radical endoscopic resection (SRER). The aim was to evaluate the combined experience in four tertiary referral centres with SRER to eradicate Barrett's oesophagus with early neoplasia.

Methods Design: Retrospective cohort study.

Setting: Four tertiary referral centres.

Participants: 169 patients (151 males, age 64 years (IQR 57–71), Barrett's oesophagus 3 cm (IQR 2–5)) with early neoplasia in Barrett's oesophagus ≤5 cm, without deep submucosal infiltration or lymph node metastases, treated by SRER between January 2000 and September 2006.

Intervention: Endoscopic resection every 4–8 weeks, until complete endoscopic and histological eradication of Barrett's oesophagus and neoplasia.

Results According to intention-to-treat analysis complete eradication of all neoplasia and all intestinal metaplasia by the end of the treatment phase was reached in 97.6% (165/169) and 85.2% (144/169) of patients, respectively. One patient had progression of neoplasia during treatment and died of metastasised adenocarcinoma (0.6%). After median follow-up of 32 months (IQR 19–49), complete eradication of neoplasia and intestinal metaplasia was sustained in 95.3% (161/169) and 80.5% (136/169) of patients, respectively. Acute, severe complications occurred in 1.2% of patients, and 49.7% of patients developed symptomatic stenosis.

Conclusions SRER of Barrett's oesophagus ≤5 cm containing early neoplasia appears to be an effective treatment modality with a low rate of recurrent lesions during follow-up. The procedure, however, is technically demanding and is associated with oesophageal stenosis in half of the patients.

  • Barrett's oesophagus
  • cancer
  • intestinal metaplasia
  • intraepithelial neoplasia
  • endoscopic resection
  • Barrett's carcinoma
  • Barrett's metaplasia
  • endoscopy

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Details of authors: R.E. Pouw (conception and design, analysis and interpretation of data, drafting the article, final approval to be published); S. Seewald (conception and design, critical revision of the manuscript for important intellectual content, final approval); J.J. Gondrie (conception and design, analysis and interpretation of data, drafting the article, final approval); P.H. Deprez (conception and design, critical revision of the manuscript for important intellectual content, final approval); H. Piessevaux (conception and design, critical revision of the manuscript for important intellectual content, final approval); H. Pohl (conception and design, critical revision of the manuscript for important intellectual content, final approval); T. Rösch (conception and design, critical revision of the manuscript for important intellectual content, final approval); N. Soehendra (conception and design, critical revision of the manuscript for important intellectual content, final approval); J.J. Bergman (conception and design, analysis and interpretation of data, critical revision of the manuscript for important intellectual content, final approval).

  • Competing interests None.

  • Provenance and peer review Not commissioned; externally peer reviewed

Linked Articles